Allergen immunotherapy is available for selected patients with house dust mite allergy but typically injections need to be given regularly for three to five years.
In 1986, the results of the first double-blind, placebo-controlled randomized clinical trial of house dust mite allergen sublingual immunotherapy were published.
When a house dust mite allergen was introduced, which is a common human allergen, both airway remodelling and allergic airway inflammation were more significantly enhanced.
